MetaVia (NASDAQ:MTVA – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.06) by $1.64, FiscalAI reports.
MetaVia Stock Performance
Shares of MetaVia stock traded up $0.04 during trading hours on Thursday, reaching $1.34. The company’s stock had a trading volume of 3,469 shares, compared to its average volume of 264,881. MetaVia has a one year low of $1.22 and a one year high of $23.10. The company’s 50 day simple moving average is $1.89 and its 200 day simple moving average is $6.88. The stock has a market cap of $2.95 million, a P/E ratio of -0.16 and a beta of 0.33.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on MTVA shares. HC Wainwright upped their price objective on shares of MetaVia from $12.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Wall Street Zen cut MetaVia from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of MetaVia in a research report on Monday, December 22nd. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, MetaVia has an average rating of “Hold” and a consensus target price of $36.50.
Institutional Investors Weigh In On MetaVia
A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC bought a new position in MetaVia Inc. (NASDAQ:MTVA – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia as of its most recent SEC filing. Institutional investors own 1.37% of the company’s stock.
MetaVia Company Profile
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.
See Also
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
